Global Neurometabolic Disorders Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI03245667

Publication Date:

March 7, 2024

Pages:

134

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Neurometabolic Disorders market size was valued at US$ 1226.7 million in 2023. With growing demand in downstream market, the Neurometabolic Disorders is forecast to a readjusted size of US$ 1688.3 million by 2030 with a CAGR of 4.7% during review period.
The research report highlights the growth potential of the global Neurometabolic Disorders market. Neurometabolic Disorders are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurometabolic Disorders. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurometabolic Disorders market.
Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
The Neurometabolic Disorders Market is driven by the increasing awareness and understanding of rare inherited metabolic disorders that affect the nervous system. These disorders, such as phenylketonuria and lysosomal storage diseases, require specialized treatments and therapies to manage symptoms and improve the quality of life for affected individuals. As advancements in genetics and diagnostics progress, the demand for research, development, and access to therapies and interventions for neurometabolic disorders continues to grow. These therapies often involve enzyme replacement therapy, gene therapy, or small molecule drugs, aiming to address the underlying metabolic abnormalities associated with these conditions. However, a key challenge for this market is the need to overcome the high cost of treatment and ensure that individuals with these rare disorders have equitable access to life-changing therapies. Regulatory approval, early diagnosis, and addressing potential side effects of treatments are ongoing challenges. Additionally, the market faces competition from other rare diseases, necessitating continuous research and efforts to mobilize resources and global commitment to improving the lives of those affected by neurometabolic disorders. Balancing innovation, affordability, and accessibility while addressing the unique challenges of these conditions is vital for the continued growth of the Neurometabolic Disorders Market.
Key Features:
The report on Neurometabolic Disorders market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurometabolic Disorders market. It may include historical data, market segmentation by Type (e.g., Gaucher鈥檚 Disease, Fabry Disease), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurometabolic Disorders market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurometabolic Disorders market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurometabolic Disorders industry. This include advancements in Neurometabolic Disorders technology, Neurometabolic Disorders new entrants, Neurometabolic Disorders new investment, and other innovations that are shaping the future of Neurometabolic Disorders.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurometabolic Disorders market. It includes factors influencing customer ' purchasing decisions, preferences for Neurometabolic Disorders product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurometabolic Disorders market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurometabolic Disorders market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurometabolic Disorders market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurometabolic Disorders industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurometabolic Disorders market.
Market Segmentation:
Neurometabolic Disorders market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Gaucher鈥檚 Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Segmentation by application
Oral
Parenteral
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurometabolic Disorders Market Size 2019-2030
2.1.2 Neurometabolic Disorders Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neurometabolic Disorders Segment by Type
2.2.1 Gaucher鈥檚 Disease
2.2.2 Fabry Disease
2.2.3 Pompe Disease
2.2.4 Mucopolysaccharidosis VI
2.2.5 Other
2.3 Neurometabolic Disorders Market Size by Type
2.3.1 Neurometabolic Disorders Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neurometabolic Disorders Market Size Market Share by Type (2019-2024)
2.4 Neurometabolic Disorders Segment by Application
2.4.1 Oral
2.4.2 Parenteral
2.5 Neurometabolic Disorders Market Size by Application
2.5.1 Neurometabolic Disorders Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neurometabolic Disorders Market Size Market Share by Application (2019-2024)
3 Neurometabolic Disorders Market Size by Player
3.1 Neurometabolic Disorders Market Size Market Share by Players
3.1.1 Global Neurometabolic Disorders Revenue by Players (2019-2024)
3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2019-2024)
3.2 Global Neurometabolic Disorders Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Neurometabolic Disorders by Regions
4.1 Neurometabolic Disorders Market Size by Regions (2019-2024)
4.2 Americas Neurometabolic Disorders Market Size Growth (2019-2024)
4.3 APAC Neurometabolic Disorders Market Size Growth (2019-2024)
4.4 Europe Neurometabolic Disorders Market Size Growth (2019-2024)
4.5 Middle East & Africa Neurometabolic Disorders Market Size Growth (2019-2024)
5 Americas
5.1 Americas Neurometabolic Disorders Market Size by Country (2019-2024)
5.2 Americas Neurometabolic Disorders Market Size by Type (2019-2024)
5.3 Americas Neurometabolic Disorders Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurometabolic Disorders Market Size by Region (2019-2024)
6.2 APAC Neurometabolic Disorders Market Size by Type (2019-2024)
6.3 APAC Neurometabolic Disorders Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neurometabolic Disorders by Country (2019-2024)
7.2 Europe Neurometabolic Disorders Market Size by Type (2019-2024)
7.3 Europe Neurometabolic Disorders Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurometabolic Disorders by Region (2019-2024)
8.2 Middle East & Africa Neurometabolic Disorders Market Size by Type (2019-2024)
8.3 Middle East & Africa Neurometabolic Disorders Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Neurometabolic Disorders Market Forecast
10.1 Global Neurometabolic Disorders Forecast by Regions (2025-2030)
10.1.1 Global Neurometabolic Disorders Forecast by Regions (2025-2030)
10.1.2 Americas Neurometabolic Disorders Forecast
10.1.3 APAC Neurometabolic Disorders Forecast
10.1.4 Europe Neurometabolic Disorders Forecast
10.1.5 Middle East & Africa Neurometabolic Disorders Forecast
10.2 Americas Neurometabolic Disorders Forecast by Country (2025-2030)
10.2.1 United States Neurometabolic Disorders Market Forecast
10.2.2 Canada Neurometabolic Disorders Market Forecast
10.2.3 Mexico Neurometabolic Disorders Market Forecast
10.2.4 Brazil Neurometabolic Disorders Market Forecast
10.3 APAC Neurometabolic Disorders Forecast by Region (2025-2030)
10.3.1 China Neurometabolic Disorders Market Forecast
10.3.2 Japan Neurometabolic Disorders Market Forecast
10.3.3 Korea Neurometabolic Disorders Market Forecast
10.3.4 Southeast Asia Neurometabolic Disorders Market Forecast
10.3.5 India Neurometabolic Disorders Market Forecast
10.3.6 Australia Neurometabolic Disorders Market Forecast
10.4 Europe Neurometabolic Disorders Forecast by Country (2025-2030)
10.4.1 Germany Neurometabolic Disorders Market Forecast
10.4.2 France Neurometabolic Disorders Market Forecast
10.4.3 UK Neurometabolic Disorders Market Forecast
10.4.4 Italy Neurometabolic Disorders Market Forecast
10.4.5 Russia Neurometabolic Disorders Market Forecast
10.5 Middle East & Africa Neurometabolic Disorders Forecast by Region (2025-2030)
10.5.1 Egypt Neurometabolic Disorders Market Forecast
10.5.2 South Africa Neurometabolic Disorders Market Forecast
10.5.3 Israel Neurometabolic Disorders Market Forecast
10.5.4 Turkey Neurometabolic Disorders Market Forecast
10.5.5 GCC Countries Neurometabolic Disorders Market Forecast
10.6 Global Neurometabolic Disorders Forecast by Type (2025-2030)
10.7 Global Neurometabolic Disorders Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Amicus Therapeutics
11.1.1 Amicus Therapeutics Company Information
11.1.2 Amicus Therapeutics Neurometabolic Disorders Product Offered
11.1.3 Amicus Therapeutics Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Amicus Therapeutics Main Business Overview
11.1.5 Amicus Therapeutics Latest Developments
11.2 ISU Abxis
11.2.1 ISU Abxis Company Information
11.2.2 ISU Abxis Neurometabolic Disorders Product Offered
11.2.3 ISU Abxis Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 ISU Abxis Main Business Overview
11.2.5 ISU Abxis Latest Developments
11.3 JCR Pharmaceuticals
11.3.1 JCR Pharmaceuticals Company Information
11.3.2 JCR Pharmaceuticals Neurometabolic Disorders Product Offered
11.3.3 JCR Pharmaceuticals Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 JCR Pharmaceuticals Main Business Overview
11.3.5 JCR Pharmaceuticals Latest Developments
11.4 Biosidus
11.4.1 Biosidus Company Information
11.4.2 Biosidus Neurometabolic Disorders Product Offered
11.4.3 Biosidus Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Biosidus Main Business Overview
11.4.5 Biosidus Latest Developments
11.5 Greenovation Biotech
11.5.1 Greenovation Biotech Company Information
11.5.2 Greenovation Biotech Neurometabolic Disorders Product Offered
11.5.3 Greenovation Biotech Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Greenovation Biotech Main Business Overview
11.5.5 Greenovation Biotech Latest Developments
11.6 UAB Proforma
11.6.1 UAB Proforma Company Information
11.6.2 UAB Proforma Neurometabolic Disorders Product Offered
11.6.3 UAB Proforma Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 UAB Proforma Main Business Overview
11.6.5 UAB Proforma Latest Developments
11.7 Dong-A Socio Group
11.7.1 Dong-A Socio Group Company Information
11.7.2 Dong-A Socio Group Neurometabolic Disorders Product Offered
11.7.3 Dong-A Socio Group Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Dong-A Socio Group Main Business Overview
11.7.5 Dong-A Socio Group Latest Developments
11.8 ExSAR Corporation
11.8.1 ExSAR Corporation Company Information
11.8.2 ExSAR Corporation Neurometabolic Disorders Product Offered
11.8.3 ExSAR Corporation Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 ExSAR Corporation Main Business Overview
11.8.5 ExSAR Corporation Latest Developments
11.9 Lixte Biotechnology
11.9.1 Lixte Biotechnology Company Information
11.9.2 Lixte Biotechnology Neurometabolic Disorders Product Offered
11.9.3 Lixte Biotechnology Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Lixte Biotechnology Main Business Overview
11.9.5 Lixte Biotechnology Latest Developments
11.10 Neuraltus Pharmaceuticals
11.10.1 Neuraltus Pharmaceuticals Company Information
11.10.2 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Offered
11.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Neuraltus Pharmaceuticals Main Business Overview
11.10.5 Neuraltus Pharmaceuticals Latest Developments
11.11 Protalix
11.11.1 Protalix Company Information
11.11.2 Protalix Neurometabolic Disorders Product Offered
11.11.3 Protalix Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Protalix Main Business Overview
11.11.5 Protalix Latest Developments
11.12 Pharming Group
11.12.1 Pharming Group Company Information
11.12.2 Pharming Group Neurometabolic Disorders Product Offered
11.12.3 Pharming Group Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Pharming Group Main Business Overview
11.12.5 Pharming Group Latest Developments
11.13 Protalix BioTherapeutics
11.13.1 Protalix BioTherapeutics Company Information
11.13.2 Protalix BioTherapeutics Neurometabolic Disorders Product Offered
11.13.3 Protalix BioTherapeutics Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Protalix BioTherapeutics Main Business Overview
11.13.5 Protalix BioTherapeutics Latest Developments
11.14 Amicus
11.14.1 Amicus Company Information
11.14.2 Amicus Neurometabolic Disorders Product Offered
11.14.3 Amicus Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Amicus Main Business Overview
11.14.5 Amicus Latest Developments
11.15 Biomarin
11.15.1 Biomarin Company Information
11.15.2 Biomarin Neurometabolic Disorders Product Offered
11.15.3 Biomarin Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Biomarin Main Business Overview
11.15.5 Biomarin Latest Developments
11.16 Genzyme
11.16.1 Genzyme Company Information
11.16.2 Genzyme Neurometabolic Disorders Product Offered
11.16.3 Genzyme Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Genzyme Main Business Overview
11.16.5 Genzyme Latest Developments
11.17 Shire
11.17.1 Shire Company Information
11.17.2 Shire Neurometabolic Disorders Product Offered
11.17.3 Shire Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Shire Main Business Overview
11.17.5 Shire Latest Developments
11.18 Greencross
11.18.1 Greencross Company Information
11.18.2 Greencross Neurometabolic Disorders Product Offered
11.18.3 Greencross Neurometabolic Disorders Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Greencross Main Business Overview
11.18.5 Greencross Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂